Skip to content

Study · Randomized controlled trial · n = 1 · 2009

5 results

Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.

Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y and 10 more

Show all authors

Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G

Annals of neurology1 Feb 2009Cited by 109 (Europe PMC)

PMID19259967 (opens in a new tab)DOI10.1002/ana.21540 (opens in a new tab)PepBankPUB-19259967
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SBMA patients, leuprorelin significantly extended cricopharyngeal opening duration versus placebo.

    In plain wordsIn SBMA patients, leuprorelin extended throat muscle opening duration more than placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseCricopharyngeal opening duration
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Leuprorelin acetate significantly extended the duration of cricopharyngeal opening in videofluorography and decreased mutant AR accumulation in scrotal skin biopsy.
    1 context sentence
    Summary · context
    Fifty SBMA patients underwent subcutaneous injections of leuprorelin acetate or placebo in a randomized, placebo-controlled trial for 48 weeks, followed by an open-label trial for an additional 96 weeks, in which 19 patients of the leuprorelin group and 15 of the placebo group received leuprorelin acetate.
  2. 02HumanRandomized controlled trialMechanism

    In SBMA patients, leuprorelin significantly decreased mutant AR accumulation in scrotal skin biopsies versus placebo.

    In plain wordsIn SBMA patients, leuprorelin reduced mutant androgen receptor accumulation in skin biopsies compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseMutant AR accumulation in scrotal skin
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Leuprorelin acetate significantly extended the duration of cricopharyngeal opening in videofluorography and decreased mutant AR accumulation in scrotal skin biopsy.
    1 context sentence
    Summary · context
    Fifty SBMA patients underwent subcutaneous injections of leuprorelin acetate or placebo in a randomized, placebo-controlled trial for 48 weeks, followed by an open-label trial for an additional 96 weeks, in which 19 patients of the leuprorelin group and 15 of the placebo group received leuprorelin acetate.
  3. 03HumanNon-randomized trialEfficacy outcome

    In SBMA patients, those treated with leuprorelin for 144 weeks had significantly greater functional scores than those who received placebo.

    In plain wordsIn SBMA patients, those treated with leuprorelin for 144 weeks had greater functional scores than those who received placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseFunctional scores
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 144 weeksAs given in this study (human).

    Source sentences

    Summary
    The patients treated with leuprorelin acetate for 144 weeks exhibited significantly greater functional scores and better swallowing parameters than those who received placebo.
    1 context sentence
    Summary · context
    Fifty SBMA patients underwent subcutaneous injections of leuprorelin acetate or placebo in a randomized, placebo-controlled trial for 48 weeks, followed by an open-label trial for an additional 96 weeks, in which 19 patients of the leuprorelin group and 15 of the placebo group received leuprorelin acetate.
  4. 04HumanNon-randomized trialEfficacy outcome

    In SBMA patients, those treated with leuprorelin for 144 weeks had significantly better swallowing parameters than those who received placebo.

    In plain wordsIn SBMA patients, those treated with leuprorelin for 144 weeks had better swallowing measures than those who received placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseSwallowing parameters
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 144 weeksAs given in this study (human).

    Source sentences

    Summary
    The patients treated with leuprorelin acetate for 144 weeks exhibited significantly greater functional scores and better swallowing parameters than those who received placebo.
    1 context sentence
    Summary · context
    Fifty SBMA patients underwent subcutaneous injections of leuprorelin acetate or placebo in a randomized, placebo-controlled trial for 48 weeks, followed by an open-label trial for an additional 96 weeks, in which 19 patients of the leuprorelin group and 15 of the placebo group received leuprorelin acetate.
  5. 05HumanCase report or seriesMechanism

    In one SBMA patient, autopsy suggested that leuprorelin inhibited mutant AR nuclear accumulation or stabilization in motor neurons.

    In plain wordsIn one SBMA patient, autopsy suggested less mutant receptor accumulation or stabilization in motor neurons after leuprorelin.

    Peptide
    Leuprolide
    Outcome
    DecreaseMotor-neuron mutant AR accumulation or stabilization
    Study

    n = 1

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 118 weeksAs given in this study (human).

    Source sentences

    Summary
    Autopsy of one patient who received leuprorelin acetate for 118 weeks suggested that androgen deprivation inhibits the nuclear accumulation or stabilization, or both, of mutant AR in the motor neurons of the spinal cord and brainstem.
    1 context sentence
    Summary · context
    Fifty SBMA patients underwent subcutaneous injections of leuprorelin acetate or placebo in a randomized, placebo-controlled trial for 48 weeks, followed by an open-label trial for an additional 96 weeks, in which 19 patients of the leuprorelin group and 15 of the placebo group received leuprorelin acetate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.